A procedure can turn an otherwise routine CSU follow-up into a different kind of treatment conversation. Drawing from a post hoc analysis of REMIX-1 and REMIX-2, this experience looks closely at what was observed in patients receiving remibrutinib who underwent surgical or invasive procedures, then brings the findings back to the decisions clinicians actually have to make. Across several short videos, follow the data from study design and bleeding-risk categories through treatment interruption, patient counseling, and the practical coordination that still matters when the evidence meets the individual patient.